314 results about "Endometrial cancer" patented technology

This invention relates to novel monoclonal antibodies that specifically bind to the alpha-folate receptor. In some embodiments, the antibodies inhibit a biological activity of folate receptor-α (FR-α). The antibodies are useful in the treatment of certain cancers, particularly cancers that have increased cell surface expression of the alpha-folate receptor (“FR-α”), such as ovarian, breast, renal, colorectal, lung, endometrial, or brain cancer. The invention also relates to cells expressing the monoclonal antibodies, antibody derivatives, such as chimeric and humanized monoclonal antibodies, antibody fragments, and methods of detecting and treating cancer using the antibodies, derivatives, and fragments.

In one aspect, the present invention provides a method of treating uterine cancer, endometrial cancer, or ovarian cancer, comprising administering to a subject at least one PARP inhibitor. In another aspect, the present invention provides a method of treating uterine cancer, endometrial cancer, or ovarian cancer, comprising administering to a subject at least one PARP inhibitor in combination with at least one anti-tumor agent.

Estrogen receptor-modulating pyrazole compounds are described in addition to methods and compositions for treating or preventing estrogen receptor-mediated disorders. The compounds described have been found to have unexpected and surprising activity in modulating estrogen receptor activity. Thus, the compounds of the present invention have utility in preventing or treating estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimer's disease.

The invention belongs to the field of the tumor molecule biology, in particular to a diagnosis reagent, a reagent knit and prevention and cure drugs of endometrial carcinoma, which provides a new diagnosis reagent and medicine for the early diagnosis and the prevention of endometrial carcinoma, and also provides a new method for filtering the medicine used for preventing endometrial carcinoma. The diagnosis reagent for endometrial carcinoma of the invention contains a reagent which can test the expressing level of a human cyclophilin A protein or the content of the mRNA of genes of the human cyclophilin A protein. The medicine which can prevent endometrial carcinoma of the invention includes: the expressing carrier of a shPNA molecule which can express the human cyclophilin A, etc. can change the expressing level of the human cyclophilin A protein or the mRNA content of the genes of the human cyclophilin A protein. The diagnosis reagent of the invention can be used for the early diagnosis of endometrial carcinoma, which has a wide application prospect.

The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status as well as endometrical cancer status in a patient. In particular, it has been found that hepcidin is a biomarker for both ovarian cancer and endometrial cancer and that a panel of biomarkers, including hepcidin, transthyretin and optionally other markers are useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarkers can be detected by SELDI mass spectrometry.

The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status as well as endometrical cancer status in a patient. In particular, it has been found that hepcidin is a biomarker for both ovarian cancer and endometrial cancer and that a panel of biomarkers, including hepcidin, transthyretin and optionally other markers are useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarkers can be detected by SELDI mass spectrometry.

Isoxazole estrogen receptor agonist and antagonist compounds having unexpected and surprising activity in modulating estrogen receptor activity are described. In addition, methods and compositions for treating or preventing estrogen receptor-mediated disorders are disclosed. The compounds, methods, and compositions of the invention have utility in preventing or treating estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimer's disease.

The invention relates to a second generation sequencing-based method for detecting microsatellite instability (MSI) and genomic changes through plasma, a device implementing the method, uses of the method especially in non-invasive diagnosis, prognostic assessment, selection of treatment regimens or genetic screening in patients with cancer, preferably colorectal cancer (e. G., bowel cancer), gastric cancer and endometrial cancer. microsatellite instability (MSI) sites with high sensitivity and specificity associated with cancer, preferably colorectal cancer (e.g., bowel cancer), gastric or endometrial cancer, based on the detection method are obtained. The present invention also relates to a kit used in plasma microsatellite instability detection and use of detection reagents in preparation of the kit. The plasma MSI detection method is provided for that first time, which enables a microsatellite (MS) state of a sample to be judged with high accuracy and sensitivity.

The present invention relates to the use of Fibroblast Growth Factor Receptor I (FGFR1) extracellular domain (ECD) polypeptides for treatment of cancers characterized by ligand dependent activating mutations in Fibroblast Growth Factor Receptor 2 (FGFR2). For example, the present invention relates to the treatment of endometrial cancers and other cancers wherein tumor cells express FGFR2 mutants in the IgII-IgIII hinge region or IgIII domain of the protein, such as at amino acid positions 252 and / or 253.

Described herein are compounds of Formulae (I)-(II), and pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases such as cancers (e.g., lung cancer, large bowel cancer, pancreas cancer, biliary tract cancer, or endometrial cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases in a subject.

The present invention relates to biomarker combinations, kits for detecting them, and their use in microsatellite instability (MSI) detection and cancer, preferably colorectal cancer (e.g., bowel cancer), gastric cancer or endometrial cancer, prognostic assessment, treatment regimen selection or genetic screening in plasma samples. A method for detecting plasma MSI is provided for the first time,which enables a microsatellite (MS) state of a sample to be judged with high accuracy and sensitivity.

This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a liquid particle formulation, methods of using the compositions to inhibit the expression of the Eg5 / KSP and VEGF, and methods of using the compositions to treat pathological processes mediated by Eg5 / KSP and VEGF expression, such as endometrial cancer.

This invention provides for combinations of 5 alpha reductase inhibitors and SERMs. These combinations are useful in: 1) preventing prostate carcinogenesis in a subject; 2) preventing the recurrence of, suppressing, inhibiting or reducing the incidence of prostate carcinogenesis in a subject; 3) treating a subject with prostate cancer; 4) suppressing, inhibiting or reducing the incidence of prostate cancer in a subject; 5) treating a subject with pre-malignant lesions of prostate cancer; 6) suppressing, inhibiting or reducing the incidence of pre-malignant lesions of prostate cancer in a subject; 7) reducing the incidence, inhibiting, suppressing, preventing and / or treating androgen-deprivation induced conditions in men suffering from prostate cancer, such as androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), hot flashes and / or gynecomastia; and 8) treating polycystic ovarian syndrome and reducing the incidence, inhibiting, suppressing, preventing and / or treating diabetes, cardiovascular disease, breast cancer and endometrial cancer in women suffering from polycystic ovarian syndrome.

The invention discloses a kit for detecting DNA mismatch repair systems and application thereof; the kit comprises an amplifying system which comprises PCR (polymerase chain reaction) primer mixed liquid and PCR reaction liquid; the PCR primer mixed liquid contains microsatellite sites. The microsatellite sites in the kit are higher in sensitivity and accuracy and are suitable for detecting different cancers, such as colorectal cancer, endometrial cancer, gastric cancer, pancreatic cancer, lung cancer and breast cancer. The kit with microsatellite site for detecting DNA mismatch repair systems is better in repeatability, is suitable for detecting multiple microsatellite sites at the same time, and has improved detection efficiency.

The invention discloses a mouse monoclonal antibody against a human Siglec-15 protein. The specificity is high, the performance is stable and the titer is high. The invention further relates to application of the monoclonal antibody to preparation of immunohistochemical detection tools for the Siglec-15 protein. According to the mouse monoclonal antibody against the human Siglec-15 protein, an immunohistochemistry method is used for detecting expression of Siglec-15 on the tumor cell surface for selection, the curative effect and the prognosis of therapeutic schedules of malignant tumors. Theinvention further relates to the application of the monoclonal antibody to preparation of antibody drugs for immunotherapy of the malignant tumors. The important application value is achieved. The adopted antibody drugs can be full-length or partial sections (Fab, F(ab)'2 or ScFv) of an Siglec-15 monoclonal antibody or combined use of the Siglec-15 monoclonal antibody and a PD-L1 monoclonal antibody. The malignant tumors mainly include colorectal cancer, endometrial cancer, thyroid cancer, bladder cancer, kidney cancer, lung cancer, liver cancer and the like.

Diagnostic and therapeutic applications for endometrial cancer are described. The diagnostic and therapeutic applications are based on certain activation mutations in the FGFR2 gene and its expression products. The present invention is directed to nucleotide sequences, amino acid sequences, probes, and primers related to FGFR2 activation mutants and kits comprising these mutants to diagnosis and classify endometrial cancer in a subject.

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and / or brain tumor.

Biomarkers and polypeptide profiles for screening, detection, and monitoring of endometrial pathology, including endometrial cancer.

Biomarker proteins that can be used in the diagnosis of early-stage endometrial cancer are described. Methods of screening for endometrial cancer, as well as methods of detecting and monitoring the status of endometrial cancer are provided. The biomarkers can be used to detect a variety of endometrial cancers, including endometroid carcinoma, clear cell carcinoma and serous carcinoma.

In one aspect, the present invention provides a method of treating uterine cancer, endometrial cancer, or ovarian cancer, comprising administering to a subject at least one PARP inhibitor. In another aspect, the present invention provides a method of treating uterine cancer, endometrial cancer, or ovarian cancer, comprising administering to a subject at least one PARP inhibitor in combination with at least one anti-tumor agent.

The present invention relates to: use of a 2,3-dihydroimidazo[1,2-c]quinazoline compound, or of a pharmaceutical composition containing same, as a sole active agent, or of a combination of a) said compound or a pharmaceutical composition containing said compound and b) one or more further active agents, for the preparation of a medicament for the treatment or prophylaxis of endometrial cancer (hereinafter abbreviated to “EC”), particularly 1st line, 2nd line, relapsed, refractory, type I or type II EC, or endometriosis; combinations of a) said compound and b) one or more further active agents; a pharmaceutical composition comprising said compound as a sole active agent for the treatment of endometrial cancer (hereinafter abbreviated to “EC”), particularly 1st line, 2nd line, relapsed, refractory, type I or type II EC, or endometriosis; a pharmaceutical composition comprising a combination of a) said compound and b) one or more further active agents; use of biomarkers which is the loss of tumor suppressor PTEN or FBXW7, for predicting the sensitivity and / or resistance of a cancer patient to said compound and providing a rationale-based dosage to increase sensitivity and / or to overcome resistance; a method of determining the loss of tumor suppressor PTEN or FBXW7; and a method for determining perturbations in PIK3CA, PIK3CB, PIK3CD, PIK3CG, P1K3R1, PIK3R2, PIK3R3, PIK3R4, PIK3R5, FGFR1, FGFR2, FGFR3 and / or FGFR4.

The invention discloses a method for extracting and separating viterxin and isovitexin from a natural product. The method comprises the following steps: based on santalum album L leaves as raw materials, carrying out ultrasonic extraction and lixiviation on the santalum album L leaves by utilizing an alcohol solvent; then respectively extracting santalum album L leaf extract by adopting petroleum ether, chloroform and ethyl acetate in turn; carrying out column chromatography on ethyl acetate extract, and recrystallizing the obtained eluent so as to obtain the isovitexin; and separating a residual liquid through a preparation liquid phase so as to obtain the viterxin. In the method, the santalum album L leaves are used for the first time so as to extract out the viterxin and isovitexin, the separation process is simple, the cost is low, and the raw materials are available; the santalum album L leaves contain high viterxin and isovitexin contents, thus a novel way for resource utilization of santalum album L leaves is provided; the two compounds can be prepared into small hydro-acupuncture drop injections, freeze-dried powder, tablets, capsules or pills; and the viterxin can be used for preparation of medicaments for treating coronary disease, myocardial infarction, angina and cancer prevention tumour resistance, and the isovitexin can be used for preparation of medicaments for treating or preventing prostate cancer, breast cancer and endometrial cancer.

The invention relates to the surprising finding that biomarkers corresponding to ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4, P4HB, PHKG2, PPFIBP2, PPP1 R16A, RASSF7, RNF183, SIRT6, TJP3, EFEMP2, S0CS2, and DCN are differentially expressed in control samples as compared to samples from patients having endometrial cancer and are therefore useful for detecting endometrial cancer. In particular these biomarkers having excellent sensitivity, specificity, and / or the ability to separate affected from non affected individuals. Furthermore, the inventors found that the differential expression of these biomarkers in primary endometrial cancer tumor tissue is correlated to their expression level in uterine fluid samples as compared to control values.; Thus these biomarkers are robust in that they are found to be differentially expressed in several different types of samples from affected individuals.

The invention provides a human tumor-related methylation site as well as a screening method and use thereof. The human tumor-related methylation site is selected from at least one methylation site on a human 18th chromosome, a human third chromosome and a human second chromosome; the change of methylation site, caused by BMI, on chromosomes is related to a human endometrial cancer; prognosis on a human tumor can be performed by detecting the methylation site changes on the chromosomes; the human tumor-related methylation site can be used as a potential prognosis marker of the tumor, and especially can be used as a prognosis marker of the human endometrial cancer.

Described is a vaccine for prevention and treatment of cancer characterized by microsatellite instability (MSI). The vaccine contains an MSI-specific frameshift peptide (FSP) generating humoral and cellular responses against tumor cells or a nucleic acid encoding said FSP. The vaccine of the present invention is particularly useful for the prevention / treatment of colorectal cancer, endometrial cancer, gastric cancer or small bowel cancer.

The invention relates to application of evodiamine in preparing a medicine for inhibiting an aryl hydrocarbon receptor. The medicine for inhibiting the aryl hydrocarbon receptor has the anti-tumor and immunoregulation effects by inhibiting the aryl hydrocarbon receptor, wherein the tumors are breast cancer, endometrial cancer, prostate cancer, lung cancer, gastric cancer, liver cancer, colon cancer and the like; and the immunoregulation is performed aiming at various inflammatory related diseases, such as sepsis, sepsis shock, rheumatic arthritis, rheumatoid arthritis, asthma, acute and chronic glomerulonephritis, and systemic lupus erythematosus. In the application, the evodiamine is an alkaloid component in a traditional Chinese medicine, namely medicinal evodia fruit, has the molecular formula of C19H17NO3 and the molecular weight of 303.4Da, is insoluble, can be dissolved in organic solvents such as dimethyl sulfoxide, ethanol, diethyl ether and chloroform, and has the melting point of 278 to 279 DEG C.